Viking Therapeutics, Inc. Debt Securities, Available-for-sale, Gain (Loss)
Viking Therapeutics, Inc. (VKTX) reported Debt Securities, Available-for-sale, Gain (Loss) of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-30.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleGainLoss · last filed 2026-04-30
- Viking Therapeutics, Inc. debt securities, available-for-sale, gain (loss) for the quarter ending 2026-03-31 was $0.00.
- Viking Therapeutics, Inc. debt securities, available-for-sale, gain (loss) for the quarter ending 2025-09-30 was $14.00K.
| Period end | Debt Securities, Available-for-sale, Gain (Loss) 3 month | Debt Securities, Available-for-sale, Gain (Loss) 9 month |
|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | |
| 2025-09-30 | $14.00K 10-Q · filed 2025-10-23 | $14.00K 10-Q · filed 2025-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |